Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence.
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press (OUP)
https://doi.org/10.1093/rheumatology/keaf581
https://doi.org/10.1093/rheumatology/keaf581
Abstract
Description
Acknowledgements: We thank Jackie Read, PhD, of Bright Red Fox Creative Ltd for medical writing support.
Funder: Vifor Fresenius Medical Care Renal Pharma AG
Funder: AstraZeneca; doi: https://doi.org/10.13039/100004325
Key challenges in the management of ANCA-associated vasculitis (AAV) include the need to achieve more rapid and sustained remission, reduce exposure to glucocorticoids (GC) and reliably monitor and predict treatment response. Clinical trials in patients receiving rituximab or cyclophosphamide for AAV show that the adjunctive use of avacopan (a novel complement 5a receptor 1 [C5aR1] antagonist) for up to 1 year enables sustained AAV remission, considerable reductions in GC exposure, and greater recovery of kidney function, especially in patients with acute kidney injury. Additional real-world evidence suggests avacopan can be used to replace GC in patients with GC toxicity and supports the use of avacopan in AAV patients with rapidly progressing glomerulonephritis, pulmonary hemorrhage and/or refractory AAV. Future studies are needed to investigate the benefits of extending avacopan treatment beyond 1 year and in specific populations.
Funder: Vifor Fresenius Medical Care Renal Pharma AG
Funder: AstraZeneca; doi: https://doi.org/10.13039/100004325
Key challenges in the management of ANCA-associated vasculitis (AAV) include the need to achieve more rapid and sustained remission, reduce exposure to glucocorticoids (GC) and reliably monitor and predict treatment response. Clinical trials in patients receiving rituximab or cyclophosphamide for AAV show that the adjunctive use of avacopan (a novel complement 5a receptor 1 [C5aR1] antagonist) for up to 1 year enables sustained AAV remission, considerable reductions in GC exposure, and greater recovery of kidney function, especially in patients with acute kidney injury. Additional real-world evidence suggests avacopan can be used to replace GC in patients with GC toxicity and supports the use of avacopan in AAV patients with rapidly progressing glomerulonephritis, pulmonary hemorrhage and/or refractory AAV. Future studies are needed to investigate the benefits of extending avacopan treatment beyond 1 year and in specific populations.
Keywords
AAV, ANCA, ANCA-associated vasculitis, avacopan, glucocorticoids, real-world studies, Humans, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Glucocorticoids, Cyclophosphamide, Rituximab, Immunosuppressive Agents, Remission Induction, Treatment Outcome, Aniline Compounds, Nipecotic Acids